文献速递肿瘤 PET/CT核素与放射性配体治疗

新型抗CEACAM5 VHH的研发及其用于SPECT显像与潜在肿瘤治疗应用

Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-13

本研究开发了新型抗CEACAM5 VHH 6B11,在多种癌细胞系中验证其亲和力与特异性结合,并在A549-CEA5-OV与A549-CEA5-KO荷瘤小鼠中行99mTc-6B11 SPECT/CT显像、γ计数与放射自显影。6B11亲和力高(EC50 0.5nM),可完全穿透肿瘤球体,SPECT示A549-CEA5-OV肿瘤摄取更高,主要经肾清除;6B11与6F8体外均未显示显著抗癌疗效。

要点

  • 6B11对CEACAM5亲和力高(EC50 0.5nM),在癌细胞系中显示特异性细胞结合。
  • OG488-6B11在24 h完全穿透肿瘤球体,传统抗体仅见于球体周边。
  • 99mTc-6B11主要经肾清除,SPECT示A549-CEA5-OV肿瘤摄取高于A549-CEA5-KO。

核心结论

  • 抗CEACAM5 VHH 6B11是SPECT肿瘤诊断的良好候选,并可能作为靶向部分用于VHH药物偶联物开发以治疗肿瘤。

研究设计与样本

  • 研究在CEACAM5表达水平不同的癌细胞系中验证6B11的亲和力与特异性细胞结合。
  • 在A549-CEACAM5过表达(A549-CEA5-OV)与敲除(A549-CEA5-KO)荷瘤小鼠中行99mTc-6B11的SPECT/CT显像、γ计数与放射自显影。
  • 通过活力、划痕愈合与黏附实验检测6B11与6F8的体外治疗效果,并用OG488标记VHH行内化实验。

主要发现

  • 6B11显示高结合亲和力(EC50 0.5nM)与细胞结合。
  • OG488-6B11在24 h完全穿透肿瘤球体,而传统抗体仅见于球体周边。
  • SPECT示A549-CEA5-OV肿瘤摄取更高(p < 0.05),肿瘤/血比值在4 hpi为2.0016 ± 1.1893(p = 0.035)、24 hpi为2.9371 ± 2.0683(p = 0.003),A549-CEA5-KO肿瘤分别为4 hpi 0.5640 ± 0.3576、24 hpi 0.8051 ± 0.4351。
  • 99mTc-6B11主要经肾清除,放射自显影与免疫组化证实上述摄取模式。
  • 6B11与6F8体外均未显示显著抗癌治疗疗效;OG488-6B11有效内化并随时间累积于细胞,最终定位于溶酶体。

关键数值与推荐

  • 6B11对CEACAM5的EC50为0.5nM。
  • A549-CEA5-OV肿瘤肿瘤/血比值4 hpi为2.0016 ± 1.1893(p = 0.035)、24 hpi为2.9371 ± 2.0683(p = 0.003);A549-CEA5-KO肿瘤4 hpi为0.5640 ± 0.3576、24 hpi为0.8051 ± 0.4351。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, we investigated the utility of a novel developed anti-CEACAM5 VHH for cancer diagnosis and its potential of being a targeting-moiety of VHH-drug conjugates for cancer therapy. METHODS: Anti-CEACAM5 VHH (6B11) affinity and specific cellular binding was confirmed by ELISA, FACS and immunofluorescence in cancer cell lines with varying CEACAM5 expression levels. Intracellular penetration ability within tumor spheroids was tested with Oregon Green 488 labeled 6B11 (OG488-6B11). Biodistribution and binding specificity of 99mTc-radiolabeled 6B11 was tested in A549 CEACAM5 overexpressing (A549-CEA5-OV) and knockout (A549-CEA5-KO) tumor-bearing mice upon SPECT/CT imaging, γ-counting and autoradiography. The therapeutic efficacy of 6B11 and 6F8 (anti-CEACAM5 VHH with lower binding affinity) was tested by viability, wound healing and adhesion assays. To verify the potential of VHHs as a warhead for VHH-drug conjugation, an internalization assay with OG488 labeled VHH was performed. RESULT: 6B11 demonstrated high binding affinity (EC50 0.5nM) and cellular binding. OG488-6B11 penetrated tumor spheroids completely at 24 h, while a conventional antibody was only visible at the spheroid periphery. SPECT imaging indicated higher uptake (p < 0.05) in A549-CEA5-OV tumors, resulting in increased tumor-to-blood ratios especially at 4 (2.0016 ± 1.1893, p = 0.035) and 24 (2.9371 ± 2.0683, p = 0.003) hpi compared to A549-CEA5-KO tumors at 4 (0.5640 ± 0.3576) and 24 (0.8051 ± 0.4351) hpi. 99mTc-6B11 was predominantly renally cleared. Autoradiography and immunohistochemistry confirmed these uptake patterns. 6B11 nor 6F8 did exhibit significant anti-cancer therapeutic efficacy in vitro. OG488-6B11 was effectively internalized and accumulated in cells in a time-dependent manner, to end up in the lysosomes. CONCLUSION: The anti-CEACAM5 VHH 6B11 is a good candidate for SPECT-based cancer diagnosis and can be potentially used as targeting moiety in the development of VHH-based drug conjugates for cancer treatments.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cong Y, Biemans R, Lieuwes NG, et al. Development of a novel anti-CEACAM5 VHH for SPECT imaging and potential cancer therapy applications. Eur J Nucl Med Mol Imaging. 2025. PMID: 40358697. doi:10.1007/s00259-025-07321-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。